Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).
Kristina M. Jordahl(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Naomey Sarkis(Bristol-Myers Squibb (United States)), Shari M. Kaiser(Bristol-Myers Squibb (United States)), Sandy W. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Wei-Ming Kao(Bristol-Myers Squibb (United States)), Ethan Thompson(Bristol-Myers Squibb (United States))
Cited by 1
Related Papers
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505
Molecular Mechanisms of Tumor Angiogenesis
|Genes & Cancer|2011|217
Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy
|Journal of Cell Science|2015|179
A Ligand-Independent VEGFR2 Signaling Pathway Limits Angiogenic Responses in Diabetes
|Science Signaling|2014|134